| Patient | Lili Boulanger |
|---|---|
| Date of birth | 2004-08-21 |
| Identifiers | MRN HR-ET025-SYN; SSN (made up) 000-25-7731 |
| Document date | 2026-04-27 |
| Author | Odile Marchetti-Rowe, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Review at week 12, the first maintenance dose of risankizumab. [S]
Ms. Boulanger had her third infusion at week 8 and starts maintenance today with the 360 mg on-body injector, which she applied herself in clinic after teaching. Prednisone ended five weeks ago without return of symptoms. The norovirus illness two weeks ago settled in three days. She now has one or two formed stools a day and no pain (Harvey-Bradshaw Index 2). Her liver tests at week 8, drawn with the infusion, were normal, and the final mycobacterial culture was negative at six weeks. Her concert went ahead at the end of March. Her periods have returned. She has regained 3.4 kg since diagnosis. [S]
| Element | Detail |
|---|---|
| Interval change | Induction complete; prednisone stopped five weeks ago; norovirus two weeks ago, resolved |
| Activity | Harvey-Bradshaw Index 2 (clinical remission) |
| Week-8 tests | Liver enzymes and bilirubin normal |
| Today | First maintenance dose, self-injected; zoster vaccine dose 2 |
| Work | Concert performed; composing again |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever; energy good |
| Gastrointestinal | Negative | One or two formed stools a day; no pain or blood |
| Genitourinary | Negative | Periods returned |
| Musculoskeletal | Negative | No joint pain |
| Psychiatric | Negative | Mood good |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Acetaminophen 500 mg oral tablet, one or two tablets by mouth up to every 6 hours as needed for abdominal pain, no more than 3000 mg a day; no nonsteroidal anti-inflammatory drugs | One or two tablets up to every 6 hours as needed | Oral route | 2025-12-15 | active | S |
| Prednisone 20 mg oral tablet: 40 mg by mouth each morning, reduced by 5 mg each week over eight weeks, as a bridge until risankizumab takes effect | 40 mg each morning, tapering by 5 mg weekly | Oral route | 2026-01-28 to 2026-03-24 | completed | S |
| Risankizumab 600 mg in 10 mL intravenous infusion over at least one hour at weeks 0, 4, and 8 (induction) | One infusion every 4 weeks for three doses | Intravenous route | 2026-02-02 to 2026-04-26 | completed | S |
| Risankizumab 360 mg in 2.4 mL by subcutaneous on-body injector every 8 weeks (maintenance), from week 12 | One injection every 8 weeks | Subcutaneous route | 2026-04-27 | active | S |
| Ferric derisomaltose 1000 mg in 10 mL intravenous infusion, single dose | Single infusion | Intravenous route | 2026-02-02 to 2026-02-02 | completed | S |
| Cholecalciferol (vitamin D3) 2000 units oral tablet, one tablet by mouth once daily | One tablet once daily | Oral route | 2026-01-28 | active | S |
| Calcium carbonate 1250 mg (500 mg elemental calcium) oral tablet, one tablet by mouth once daily with food while on prednisone | One tablet daily with food | Oral route | 2026-01-28 to 2026-03-24 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-04-27 | Body height | 160 | cm | S |
| 2026-04-27 | Body weight | 48.4 | kg | S |
| 2026-04-27 | Body mass index (BMI) [Ratio] | 18.9 | kg/m2 | S |
| 2026-04-27 | Systolic blood pressure | 106 | mm[Hg] | S |
| 2026-04-27 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 2026-04-27 | Heart rate | 76 | /min | S |
| 2026-04-27 | Respiratory rate | 14 | /min | S |
| 2026-04-27 | Body temperature | 36.7 | Cel | S |
| 2026-04-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-04-27 | Hemoglobin [Mass/volume] in Blood | 12.6 | g/dL | 12-15.5 g/dL | Normal | S |
| 2026-04-27 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 83 | fL | 80-100 fL | Normal | S |
| 2026-04-27 | Ferritin [Mass/volume] in Serum or Plasma | 86 | ng/mL | 15-150 ng/mL | Normal | S |
| 2026-04-27 | C reactive protein [Mass/volume] in Serum or Plasma | 3 | mg/L | <=5 mg/L | Normal | S |
| 2026-04-27 | Calprotectin [Mass/mass] in Stool | 210 | ug/g | <=50 ug/g | High | S |
| 2026-04-27 | Albumin [Mass/volume] in Serum or Plasma | 4.1 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-04-27 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 19 | U/L | <=33 U/L | Normal | S |
| 2026-04-27 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 21 | U/L | <=32 U/L | Normal | S |
| 2026-04-27 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 | mg/dL | <=1.2 mg/dL | Normal | S |
| 2026-04-27 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 34 | ng/mL | 30-100 ng/mL | Normal | S |
Vital signs recorded on 2026-04-27; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; BMI 18.9 |
| Eyes | No jaundice |
| Abdomen | Soft, non-tender; no mass |
| Skin | Injection site on the abdomen without reaction |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Crohn disease of the terminal ileum and colon (ileocolitis), Montreal A2 L3 B1 without perianal disease, moderate to severe: deep ileal ulcers over 15 cm and patchy colonic ulcers, SES-CD 14, Harvey-Bradshaw Index 11; intestinal tuberculosis excluded by negative interferon-gamma release assay, normal chest X-ray, and biopsies negative for acid-fast bacilli, TB PCR, and mycobacterial culture; synthetic modern diagnosis linked to her documented chronic intestinal illness, whose historical diagnosis is not settled | active | confirmed | K50.80 | S — Synthetic diagnosis confirmed within the modern episode; her historical illness is documented (D), but whether it was intestinal tuberculosis or Crohn disease remains a retrospective interpretation (R) and is disputed. |
| Four months of crampy right lower abdominal pain, loose stools up to six times a day including at night, low-grade evening fevers, and loss of 6 kg; inflammatory markers raised; colonoscopy and small-bowel imaging booked | resolved | confirmed | R19.7 | S — Synthetic presenting concern at the index visit, superseded by the diagnosis; the documented symptoms of early 1915 are echoed (D). |
| Iron deficiency anemia from chronic intestinal blood loss and poor absorption (hemoglobin 10.6 g/dL, MCV 76, ferritin 9) | resolved | confirmed | D50.0 | S — Synthetic finding at presentation; corrected by intravenous iron. |
| Moderate protein-calorie malnutrition: BMI 17.6 after losing 6 kg (12 percent of body weight) in four months; albumin 3.3 g/dL | active | confirmed | E44.0 | S — Synthetic nutritional status at presentation; resolved with treatment and dietitian support. |
| Vitamin D deficiency (25-hydroxyvitamin D 18 ng/mL) | resolved | confirmed | E55.9 | S — Synthetic finding at presentation. |
| Long-term use of risankizumab, an immunosuppressive biologic, for Crohn disease | active | confirmed | Z79.620 | S — Synthetic treatment status. |
| Acute norovirus gastroenteritis on risankizumab, with mild dehydration; distinguished from a Crohn flare by the sudden onset, household contacts, and a positive stool PCR; resolved in three days | resolved | confirmed | A08.11 | S — Synthetic common infection that teaches the difference between infection and a flare in treated Crohn disease; it does not echo a documented illness. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Symptoms and Harvey-Bradshaw Index | Every visit | Completed today | 2: clinical remission, steroid-free |
| Laboratory | CRP | Every visit | Completed today | 3 mg/L, normal |
| Laboratory | Fecal calprotectin | About three months after starting treatment | Completed today | 210 ug/g, down from 1240; not yet at target |
| Laboratory | Liver enzymes and bilirubin during risankizumab induction | Through at least week 12 | Completed today | ALT 19, AST 21, bilirubin 0.6 today; normal at week 8 with the infusion. Induction monitoring complete; routine checks from now on |
| Laboratory | Hepatitis B antibody after the booster | One to two months after the dose | Completed today | Drawn today, three months after the booster, after the deviation recorded at week 4: anti-HBs 86 mIU/mL, protective. No harm resulted |
| Laboratory | Hemoglobin, MCV, and ferritin | After iron, then every 6 to 12 months | Completed today | Hemoglobin 12.6 g/dL, MCV 83, ferritin 86 |
| Laboratory | Vitamin D | After replacement | Completed today | 34 ng/mL |
| Laboratory | Albumin and weight | Every visit | Completed today | Albumin 4.1 g/dL; weight 48.4 kg |
| Laboratory | Mycobacterial culture of the biopsies | Final result at six to eight weeks | Up to date | Final: no growth at six weeks; intestinal tuberculosis excluded |
| Medication safety | Vaccines on biologic therapy | As scheduled | Completed today | Recombinant zoster dose 2 today; no live vaccines |
| Self-management | Self-injection teaching | At the first maintenance dose | Completed today | On-body injector applied by her under supervision |
| Imaging | Ileocolonoscopy for endoscopic response | Six to twelve months after starting treatment | Due | In the autumn |
Goal progress:
Immunizations given today: Recombinant zoster vaccine, dose 2 of 2 [S]
Guideline basis: ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol 2025;120(6):1225-1264 (2025); ACG Clinical Guideline Update: Preventive Care in Inflammatory Bowel Disease. Am J Gastroenterol 2025;120:1447-1473 (2025); STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the IOIBD. Gastroenterology 2021;160:1570-1583 (2021); SKYRIZI (risankizumab-rzaa): prescribing information (Crohn disease dosing; hepatotoxicity monitoring; tuberculosis evaluation; immunizations) (2026)
Follow-up: Risankizumab every 8 weeks at home. Review in three months with CRP and calprotectin. Next scheduled visit 2026-08-03: six-month review on maintenance risankizumab. [S]